- Home
- SWTX vs M Comparison
SWTX vs M Comparison
Compare SWTX & M Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWTX
- M
- Stock Information
- Founded
- SWTX 2017
- M 1830
- Country
- SWTX United States
- M United States
- Employees
- SWTX N/A
- M N/A
- Industry
- SWTX Biotechnology: Pharmaceutical Preparations
- M Department/Specialty Retail Stores
- Sector
- SWTX Health Care
- M Consumer Discretionary
- Exchange
- SWTX Nasdaq
- M Nasdaq
- Market Cap
- SWTX 3.5B
- M 3.2B
- IPO Year
- SWTX 2019
- M N/A
- Fundamental
- Price
- SWTX $46.26
- M $11.63
- Analyst Decision
- SWTX Buy
- M Hold
- Analyst Count
- SWTX 7
- M 11
- Target Price
- SWTX $56.86
- M $14.10
- AVG Volume (30 Days)
- SWTX 8.7M
- M 5.6M
- Earning Date
- SWTX 05-20-2025
- M 05-20-2025
- Dividend Yield
- SWTX N/A
- M 6.28%
- EPS Growth
- SWTX N/A
- M 1193.75
- EPS
- SWTX N/A
- M 2.07
- Revenue
- SWTX $191,589,000.00
- M $23,006,000,000.00
- Revenue This Year
- SWTX $86.36
- M N/A
- Revenue Next Year
- SWTX $69.02
- M N/A
- P/E Ratio
- SWTX N/A
- M $5.62
- Revenue Growth
- SWTX 3417.33
- M N/A
- 52 Week Low
- SWTX $28.21
- M $9.76
- 52 Week High
- SWTX $62.00
- M $20.70
- Technical
- Relative Strength Index (RSI)
- SWTX 58.93
- M 48.18
- Support Level
- SWTX $46.10
- M $11.47
- Resistance Level
- SWTX $46.27
- M $12.00
- Average True Range (ATR)
- SWTX 0.90
- M 0.35
- MACD
- SWTX 0.58
- M 0.14
- Stochastic Oscillator
- SWTX 99.46
- M 68.18
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
About M Macy's Inc
Founded in 1858 and based in New York City, Macy's operates about 450 stores under the Macy's nameplate, nearly 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's nameplates, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constitute about 62% of Macy's sales.